gms | German Medical Science

70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

12.05. - 15.05.2019, Würzburg

Artikel

Artikel empfehlen

MiRNA-181d expression significantly affects treatment responses to carmustine wafer implantation in glioblastoma patients

Das Ansprechverhalten auf eine Carmustin-Wafer Therapie wird signifikant von der miRNA-181d beeinflusst

Meeting Abstract

Suche in Medline nach

  • presenting/speaker Christoph Sippl - Universitätsklinikum des Saarlandes, Klinik für Neurochirurgie, Homburg, Deutschland
  • Ralf Ketter - Universitätsklinikum des Saarlandes, Klinik für Neurochiurgie, Homburg, Deutschland
  • Steffi Urbschat - Universitätsklinikum des Saarlandes, Klinik für Neurochiurgie, Homburg, Deutschland
  • Yoo Jin Kim - Universitätsklinikum des Saarlandes, Neuropathologie, Homburg, Deutschland
  • Lisa Bohr - Universitätsklinikum des Saarlandes, Neuropathologie, Homburg, Deutschland
  • Joachim Oertel - Universitätsklinikum des Saarlandes, Klinik für Neurochiurgie, Homburg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie. Würzburg, 12.-15.05.2019. Düsseldorf: German Medical Science GMS Publishing House; 2019. DocV129

doi: 10.3205/19dgnc144, urn:nbn:de:0183-19dgnc1441

Veröffentlicht: 8. Mai 2019

© 2019 Sippl et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Objective: Standard therapeutic protocols for glioblastoma, the most aggressive type of brain cancer, include surgery followed by chemoradiotherapy. Additionally, carmustine-eluting wafers can be implanted locally into the resection cavity. This study evaluated micro RNA (miRNA)-181d as a prognostic marker of responses to carmustine wafer implantation.

Methods: Eighty glioblastoma patients (40/group) were included in a matched pair analysis. One group (carmustine wafer group) received concomitant chemoradiotherapy with carmustine wafer implantation (Stupp protocol). The second group (control group) received only concomitant chemoradiotherapy. All tumor specimens were subjected to evaluations of miRNA-181d expression. Results were correlated with further individual clinical data. A TCGA (The cancer genome atlas) dataset of 149 patients was used as an independent cohort to validate the results.

Results: Patients in the carmustine wafer group with low miRNA-181d expression had significantly longer overall (hazard ratio [HR], 35.03, [95% CI: 3.50–350.23], p=0.002) and progression-free survival (HR, 20.23, [95% confidence interval (CI): 2.19–186.86], p=0.008) than patients of the same group with a high miRNA-181d expression. These correlations were not observed in the control group. The non-significance in the control group was confirmed in the independent TCGA dataset. The carmustine wafer group patients with low miRNA-181d expression also had a significantly longer progression-free (p=0.049) and overall survival (p=0.034), compared with control group patients. Gross total resection correlated significantly with longer overall survival (p=0.023).

Conclusion: MiRNA-181d expression significantly affects treatment responses to carmustine wafer implantation.